Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05477381
Other study ID # NL80642.000.22
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 18, 2022
Est. completion date December 2024

Study information

Verified date August 2023
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Sofie Breuking, drs
Phone + 31205669111
Email s.h.breuking@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Currently, transvaginal cervical length measurement is used to screen in asymptomatic pregnant women with a history of PTB. In symptomatic women, presenting with threatened PTB cervical length in combination with the fibronectin test is used to identify women at high risk to deliver preterm. However, the predictive capacity of transvaginal cervical length measurement is limited. In pregnant women with a history of PTB, it only identifies a proportion of women who will have recurrent PTB. For symptomatic women, 30-60% of these women admitted to the hospital, do not deliver within seven days, leading to overtreatment of these women. Cervical softening is precursor of cervical shortening, effacement and dilatation and therefore cervical softening is a promising new marker that is based on tissue elasticity. However, the predictive value of cervical softening and the relation with spontaneous PTB still has to be determined. With the newly developed Pregnolia® System cervical softness could be measured on a standardized and safe manner. This study could help to improve care for women with a history of spontaneous PTB.


Description:

Preterm birth (PTB) is amongst the leading causes of perinatal and childhood morbidity and mortality. Therefore, accurate identification of pregnant women at high risk of PTB is important. Identifying these women, enables obstetric healthcare professionals to apply interventions to postpone delivery and/or to prevent PTB to improve perinatal and childhood outcomes. Currently, transvaginal cervical length measurement is used to screen asymptomatic pregnant women with a history of PTB to identify women requiring a cerclage. In symptomatic women, presenting with threatened (PTB), cervical length in combination with the fetal fibronectin(fFN) test is used to identify women at high risk to deliver within 7 days of presentation. However, the predictive capacity of transvaginal cervical length measurement is limited. In pregnant women with a history of PTB, it only identifies a proportion of women who will have recurrent PTB. For symptomatic women, 30-60% of these women admitted to the hospital, do not deliver within seven days, leading to overtreatment of these women. Since cervical softening is a precursor of cervical shortening, effacement and dilatation, cervical softening is a promising new marker that is based on tissue elasticity. It can be measured with the CE-marked Pregnolia® System for accurate characterization of cervical softening status. It provides a value for tissue elasticity on a continuous scale. A previous study has shown that softening of the cervix can be detected before shortening of the cervix. The Pregnolia® System may allow to detect women at risk for PTB earlier compared to traditional transvaginal ultrasound that measures shortening of the cervix, and therefore may prove useful for a more accurate risk assessment of PTB. This current study is a single centre cohort study, where Two cohorts of women will be investigated. 1) Asymptomatic pregnant women with a history of spontaneous PTB before 34 weeks of gestation (Cohort A-STIPP). 2) Symptomatic women presenting with threatened PTB between 24 and 34 weeks (Cohort S-STIPP). Objective: The aim of this study is to evaluate the predictive capacity of cervical softening and risk of PTB.


Recruitment information / eligibility

Status Recruiting
Enrollment 390
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or above. - Ability to understand Dutch or English (both spoken and written). - Ultrasound-based gestational age determined by measurement of crown rump length (CRL) determined between 9 and 11 weeks of gestation. - Singleton and twin pregnancies. Cohort A-STIPP specific: - Medical history of spontaneous preterm birth before 34 weeks of gestation Cohort S-STIPP specific: - Threatened Preterm birth between 24 and 34 weeks of gestation. - Threatened preterm birth is defined as: - abdominal pain - (Braxton Hicks) contractions - vaginal blood loss. Exclusion Criteria: - Under 18 years of age. - Signs of intrauterine infection. - Obstetric indication for immediate delivery (advanced labor, cord prolapse, abruption, signs of fetal distress). - Confirmed fetal abnormality. - Confirmed preterm rupture of membranes. - Confirmed vasa / placenta praevia. - Severe vaginal bleeding and light bleeding that cannot be stopped. - Signs of imminent labor such as blood loss, regular contractions.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Measurement of cervical stiffness by Pregnolia Device
The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB. The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix. The Pregnolia® System will be applied within its intended use.

Locations

Country Name City State
Netherlands Amsterdam UMC, location AMC Amsterdam North-Holland

Sponsors (2)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Pregnolia AG

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient discomfort of Pregnolia measurement Pain during Pregnolia measured on a visual analogue scale (VAS) from "no pain"to "worst possible pain" In asymptomatic cohort at 14, 16, 18, 20, 22 and 24 weeks of gestational age, in the symptomatic cohort at moment of inclusion
Other Vaginal or Cervical blood loss (directly after measurement) Vaginal or Cervical blood loss, noticed directly (= within 30 minutes) after measurement In asymptomatic cohort at 14, 16, 18, 20, 22 and 24 weeks of gestational age, in the symptomatic cohort at moment of inclusion
Other Infections within seven days of measurement Infections within seven days of measurement (urinary tract infections, vaginal infections, intra-uterine infections) From inclusion up to 1 week
Other Preterm Prelabour Rupture of membranes at moment of measurement Preterm Prelabour Rupture of membranes at moment of measurement Within 1 hour after measurement
Other Irritation and sensitization of mucosal tissue Irritation and sensitization of mucosal tissue as noticed by the researcher performing the measurement Within 1 hour after measurement
Other Superficial lacerations or minor tissue abrasions Superficial lacerations or minor tissue abrasions Within 1 hour after measurement
Primary Spontaneous Preterm Birth < 34 weeks Spontaneous preterm birth before 34 weeks of gestation in the asymptomatic cohort Maximum time frame up to 28 weeks: from inclusion at 14 weeks of gestational age until delivery, with a maximum of 42 weeks of gestational age.
Primary Delivery within seven days after inclusion Delivery within seven days after inclusion in the symptomatic cohort From inclusion until 7 days later
Secondary Spontaneous preterm birth <37 weeks Spontaneous preterm birth <37 weeks of gestational age From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Spontaneous preterm birth <34 weeks Spontaneous preterm birth <34 weeks of gestational age From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Spontaneous preterm birth <32 weeks Spontaneous preterm birth <32 weeks of gestational age From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Spontaneous preterm birth <28 weeks Spontaneous preterm birth <28 weeks of gestational age From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Prediction of preterm birth using cervical softening. Development of a prediction model using cervical softening to predict the risk of preterm birth before 37, 34, 32 and 28 weeks. From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Prediction of preterm birth using the combination of cervical softening and transvaginal cervical length measurement. Development of a prediction model using the combination of cervical softening and transvaginal cervical length measurement to predict the risk of preterm birth before 37, 34, 32 and 28 weeks. From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Prediction of preterm birth using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin. Development of a prediction model using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin to predict the risk of preterm birth before 37, 34, 32 and 28 weeks. (only for symptomatic women) From inclusion (symptomatic cohort 24-34 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Prediction of latency time using cervical softening. Development of a prediction model using cervical softening to predict the latency time (interval between inclusion and delivery). From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age
Secondary Prediction of latency time using the combination of cervical softening and transvaginal cervical length measurement. Development of a prediction model using the combination of cervical softening and transvaginal cervical length measurement to predict the latency time (interval between inclusion and delivery). From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age.
Secondary Prediction of latency time using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin Development of a prediction model using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin to predict the latency time. (interval between inclusion and delivery). (only for symptomatic women) From inclusion (symptomatic cohort 24-34 weeks) until delivery with a maximum of 42 weeks of gestational age.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04811742 - Effect of Immersion Bathing and Showering Applications on Comfort Level and Physiological Parameters of Newborn N/A